Rhumbline Advisers Axsome Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 51,245 shares of AXSM stock, worth $6.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,245

Previous 51,393 0.29%

Holding current value

$6.72 Million

Previous $4.62 Million 6.11%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	SELL	$83.08 - $100.49 $12,295 - $14,872	-148 Reduced 0.29%	51,245 $4.34 Million
Q3 2024 Nov 12, 2024	SELL	$78.93 - $95.84 $279,254 - $339,081	-3,538 Reduced 6.44%	51,393 $4.62 Million
Q2 2024 Aug 01, 2024	BUY	$65.72 - $80.5 $175,735 - $215,257	2,674 Added 5.12%	54,931 $4.42 Million
Q1 2024 May 09, 2024	BUY	$69.39 - $97.64 $112,411 - $158,176	1,620 Added 3.2%	52,257 $4.17 Million
Q4 2023 Feb 08, 2024	SELL	$57.42 - $83.61 $11,943 - $17,390	-208 Reduced 0.41%	50,637 $4.03 Million
Q3 2023 Nov 09, 2023	BUY	$69.25 - $82.21 $286,348 - $339,938	4,135 Added 8.85%	50,845 $3.55 Million
Q2 2023 Aug 08, 2023	BUY	$58.41 - $90.35 $153,793 - $237,891	2,633 Added 5.97%	46,710 $3.36 Million
Q1 2023 May 11, 2023	BUY	$58.39 - $75.0 $66,447 - $85,350	1,138 Added 2.65%	44,077 $2.72 Million
Q4 2022 Feb 14, 2023	BUY	$39.94 - $79.72 $163,075 - $325,496	4,083 Added 10.51%	42,939 $3.31 Million
Q3 2022 Nov 10, 2022	BUY	$36.06 - $69.85 $157,654 - $305,384	4,372 Added 12.68%	38,856 $1.73 Million
Q2 2022 Aug 11, 2022	BUY	$21.74 - $46.75 $110,069 - $236,695	5,063 Added 17.21%	34,484 $1.32 Million
Q1 2022 May 12, 2022	SELL	$23.7 - $41.39 $3,910 - $6,829	-165 Reduced 0.56%	29,421 $1.22 Million
Q4 2021 Feb 10, 2022	SELL	$30.7 - $43.36 $10,560 - $14,915	-344 Reduced 1.15%	29,586 $1.12 Million
Q3 2021 Nov 12, 2021	BUY	$19.91 - $68.26 $7,287 - $24,983	366 Added 1.24%	29,930 $986,000
Q2 2021 Aug 05, 2021	SELL	$50.63 - $73.5 $59,135 - $85,848	-1,168 Reduced 3.8%	29,564 $1.99 Million
Q1 2021 May 06, 2021	SELL	$55.91 - $81.44 $277,760 - $404,593	-4,968 Reduced 13.92%	30,732 $1.74 Million
Q4 2020 Feb 10, 2021	BUY	$66.31 - $86.52 $69,028 - $90,067	1,041 Added 3.0%	35,700 $2.91 Million
Q3 2020 Nov 12, 2020	SELL	$68.34 - $85.84 $632,828 - $794,878	-9,260 Reduced 21.08%	34,659 $2.47 Million
Q2 2020 Aug 13, 2020	BUY	$49.87 - $98.69 $293,634 - $581,086	5,888 Added 15.48%	43,919 $3.61 Million
Q1 2020 May 06, 2020	BUY	$41.2 - $101.31 $142,346 - $350,026	3,455 Added 9.99%	38,031 $2.24 Million
Q4 2019 Feb 05, 2020	BUY	$16.71 - $106.24 $46,403 - $295,028	2,777 Added 8.73%	34,576 $3.57 Million
Q3 2019 Oct 23, 2019	BUY	$20.24 - $29.16 $10,626 - $15,309	525 Added 1.68%	31,799 $644,000
Q2 2019 Aug 14, 2019	BUY	$13.46 - $25.75 $420,948 - $805,305	31,274 New	31,274 $805,000

Others Institutions Holding AXSM

# of Institutions

348

Shares Held

36.2M

Call Options Held

1.32M

Put Options Held

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $5.62B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Axsome Therapeutics, Inc. Transaction History